Statistics

Total Visits

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease244

Select a period of time:

Number of views in the range

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease57

Views

Views
December 20258
January 202613
February 20260
March 202610
April 202611
May 20263
June 202612
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States33
Kenya3
Brazil3
France2
United Kingdom2
Jamaica2
Netherlands2
Costa Rica2
Argentina1
Canada1
 

Top cities views

Views
San Jose13
Ashburn5
Kingston2
Nairobi2
San José2
Santa Clara2
Groningen2
Al Mansurah1
Basingstoke1
Blumenau1